(NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to ...

Medicare now covers Guardant Reveal for monitoring colorectal cancer recurrence after curative therapy. Analyst sees expanded coverage boosting revenue and improving gross margins by year-end.

I nvesting.com -- Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the company's announcement that its Guardant Reveal test for colon cancer has ...

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal ...

This follows the recent announcement of expanded Medicare coverage for Guardant Health's Reveal test, which is designed to detect colon cancer recurrence. Analysts from these firms anticipate that ...

demonstrating the utility of its Guardant Reveal™ test in rectal cancer treatment. The phase II NEO trial data, featured on January 25, 2025, shows that the liquid biopsy tool can aid in ...

a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients ...

jumped 12% in early trading Tuesday on news that Medicare coverage for its Guardant Reveal blood test has been expanded to include monitoring for disease recurrence in patients with colorectal ...

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic or methylation analysis to detect circulating tumor DNA ctDNA , a marker of minimal ...